Mergers & Acquisitions ·
Crinetics Pharmaceuticals, Inc. entered into a merger agreement with Vertex Pharmaceuticals Incorporated and Clark…
CRNXCrinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc. entered into a merger agreement with Vertex Pharmaceuticals Incorporated and Clark Merger Sub, Inc. on July 6, 2026, to be acquired for $85.00 per share in cash. The transaction is expected to close in the third quarter of 2026, subject to stockholder approval and regulatory clearances. Crinetics Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies for rare endocrine diseases.